Melior Discovery: theraTRACE® Phenotypic Screening Platform
Melior Discovery's theraTRACE® phenotypic screening platform provides a cost-effective means for evaluating a repositioning candidate through a broad array of in vivo models of disease.
Melior's standard platform is designed to assess compounds across a wide therapeutic spectrum in an unbiased fashion (i.e. this is a non-hypothesis-driven approach). By evaluating compounds through approximately 40 different animal models representing 14 broad therapeutic areas, Melior is able to uncover therapeutic efficacy that is otherwise unpredicted and expected by other means.
Years of experience with the models incorporated into theraTRACE® have allowed Melior to multiplex the models, thereby allowing this work to be done for a fraction of the cost compared to running the models independent of one another, yet without comprimising the quality of the models in any way. Typically, one or more compounds can be evaluated across a full suite of 40 models in about 10 weeks.